@article{018f493e623548468477a79f0d0d2211,
title = "Suicide risk and prevention in bipolar disorder",
abstract = "Bipolar disorders are prevalent and severe illnesses that are associated with a high risk of suicide. Patients with bipolar disorder who have had prior suicide attempts are at a substantially higher risk for future suicidality, even after controlling for other risk factors. Despite the magnitude of this problem, there is a paucity of controlled prospective data to guide clinical care, most likely due to the difficulties inherent in such studies. The most robust literature supports the use of lithium as a suicide-protective agent in bipolar disorder, but a definitive controlled study in a generalizable population is warranted. As in other areas of psychiatry, a careful assessment of the individual patient risk is of paramount importance.",
author = "Marangell, {Lauren B.} and Martinez, {James M.} and Melissa Martinez and Zboyan, {Holly A.} and {Al Jurdi}, Rayan",
note = "Funding Information: (consultant only), the National Alliance for Research on Schizophrenia and Depression (grant/research support only), the National Institute of Mental Health (grant/ research support only), Neuronetics, Inc. (grant/research support only), Novartis (consultant only), Pfizer (consultant only), and the Stanley Foundation (grant/research support only). Dr. James Martinez has received research grand from and served as a consultant and speaker for Aspect Medical Systems (grant/research support), Astra-Zeneca (grant/research support, speaker{\textquoteright}s bureau only), Bristol-Myers Squibb, Co. (grant/research support, speaker{\textquoteright}s bureau only), Cyberonics, Inc., Eli Lilly, Co., Forest Laboratories, Inc. (speaker{\textquoteright}s bureau only), Glaxo-SmithKline (speaker{\textquoteright}s bureau only), Janssen-Ortho, Inc. (speaker{\textquoteright}s bureau only), National Institute of Mental Health (grant/research support only) Neuronetics, Inc. (grant/research support only), Pfizer (speaker{\textquoteright}s bureau only), Sanofi-Aventis (grant/research support only), UCB-Pharma (advisory board), Wyeth-Ayerst Pharmaceuticals (speaker{\textquoteright}s bureau only), and the Stanley Foundation (grant/research support only). Dr. Melissa Martinez has received grant/research support from Aspect Medical Systems, Bristol-Myers Squibb, Co., Eli Lilly, Co., Cyberonics, Inc., National Institute of Mental Health, Neuronetics, Inc., Sanofi-Aventis and the Stanley Foundation. In addition, several companies have given education grants for CME programs at Baylor College of Medicine. These checks are made payable to Baylor College of Medicine and are handled through the Office of Continuing Medical Education.",
year = "2006",
month = dec,
doi = "10.1007/BF02629391",
language = "English (US)",
volume = "4",
pages = "167--170",
journal = "Current Psychosis and Therapeutics Reports",
issn = "1545-8083",
publisher = "Current Science, Inc.",
number = "4",
}